AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24034302 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT responders (n=28)
Number of subjects: 38
Study 24034302 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of QRS duration and mean energy in the high frequency band
Number of subjects: 38
Study 24034302 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum energy in the high frequency band
Number of subjects: 38
Study 22542366 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG)‐releasing implant inserted 24‐48 h after delivery (implant group; n=20)
Number of subjects: 40
Study 22542366 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group; n=20)
Number of subjects: 40
Study 20175754 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 364
Study 18650111 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus supportive care
Number of subjects: 0
Study 18650111 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study 16739369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 996
Study 12954840 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin and preoperative autologous donation (Group 1)
Number of subjects: 240
Study 12954840 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin alone (Group 2)
Number of subjects: 240
Study 12954840 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation alone (Group 3)
Number of subjects: 240
Study 10932029 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (Norvasc)
Number of subjects: 0
Study 9014795 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at rest
Number of subjects: 21
Study 9014795 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen during cycle ergometry
Number of subjects: 21
Study 9014795 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous inspired oxygen during treadmill exercise testing
Number of subjects: 21
Study 9014795 — intervention group
Group type: COMPARATOR
Intervention: Air during treadmill exercise testing
Number of subjects: 21
Study 9014795 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient inhalations of pure nitrogen
Number of subjects: 21
Study 1354392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 50 mg bolus of chimaeric anti-CD4 monoclonal antibody (cM-T412)
Number of subjects: 9
Study 1354392 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg weekly for four consecutive weeks of chimaeric anti-CD4 monoclonal antibody (cM-T412)
Number of subjects: 9
Study 1354392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6147836 — intervention group
Group type: EXPERIMENTAL
Intervention: LORMetazepam 2 mg
Number of subjects: 35
Study 6147836 — intervention group
Group type: EXPERIMENTAL
Intervention: FLUNitrazepam 2 mg
Number of subjects: 35
Study 6147836 — intervention group
Group type: EXPERIMENTAL
Intervention: FLURazepam 30 mg
Number of subjects: 35
Study 6147836 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAZepam 10 mg
Number of subjects: 35
Study 30949243 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel lift group receiving pre-fabricated 12 mm in-shoe heel lifts (Clearly Adjustable®)
Number of subjects: 92
Study 30949243 — intervention group
Group type: COMPARATOR
Intervention: Calf muscle eccentric exercise program (twice a day, 7 days a week, for 12 weeks)
Number of subjects: 92
Study 30949243 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel lift group
Number of subjects: 92
Study 30949243 — intervention group
Group type: COMPARATOR
Intervention: Calf muscle eccentric exercise group
Number of subjects: 92
Study 28528475 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg/day selenium supplements
Number of subjects: 40
Study 28528475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26865420 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strip (BRNS)
Number of subjects: 26
Study 26865420 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strip (BRNS) + Decongestant
Number of subjects: 26
Study 26865420 — intervention group
Group type: COMPARATOR
Intervention: Placebo Strip
Number of subjects: 26
Study 25379858 — intervention group
Group type: COMPARATOR
Intervention: TAC-PLAC (tacrolimus placebo)
Number of subjects: 156
Study 25379858 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-STER (tacrolimus short-term steroid)
Number of subjects: 156
Study 25379858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study 22115985 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD providing continuous intracardiac ST monitoring (ST group)
Number of subjects: 103
Study 22115985 — intervention group
Group type: COMPARATOR
Intervention: ICD without continuous intracardiac ST monitoring (Control group)
Number of subjects: 103
Study 19858777 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily for 1 month, then 200 microg twice daily for 5 months
Number of subjects: 113
Study 19858777 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg twice daily for 1 year
Number of subjects: 113
Study 19858777 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide used periodically for exacerbations
Number of subjects: 113
Study 19858777 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) for 18 months
Number of subjects: 113
Study 18022468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg intramuscularly (Group T)
Number of subjects: 36
Study 18022468 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg intramuscularly (Group D)
Number of subjects: 36
Study 18022468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) (Group P)
Number of subjects: 36
Study 15617966 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed in grafted bone (222 implants)
Number of subjects: 39
Study 15617966 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implants in non-grafted bone (75 implants)
Number of subjects: 39
Study 15617966 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed in grafted bone
Number of subjects: 39
Study 15617966 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with low primary stability (20 implants)
Number of subjects: 39
Study 15617966 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed implants
Number of subjects: 39
Study 12102059 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely violent comic book
Number of subjects: 117
Study 12102059 — intervention group
Group type: COMPARATOR
Intervention: Mildly violent comic book
Number of subjects: 117
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: High contrast acuity
Number of subjects: 900
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial vision measures under conditions of reduced contrast or luminance, or glare
Number of subjects: 900
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereopsis
Number of subjects: 900
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: Color discrimination
Number of subjects: 900
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral fields under conditions of divided attention
Number of subjects: 900
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging function with a time constant of approximately 15 years
Number of subjects: 900
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard visual acuity
Number of subjects: 900
Study 10213444 — intervention group
Group type: EXPERIMENTAL
Intervention: All spatial vision functions
Number of subjects: 900
Study 7607378 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxybutynin administered intravesically
Number of subjects: 39
Study 7607378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 ml sterile sodium chloride solution) administered intravesically
Number of subjects: 39
Study 1977153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 61
Study 1977153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 1977153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (evening administration)
Number of subjects: 61
Study 1977153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (morning administration)
Number of subjects: 61
Study 707970 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (0.5-1.0 g t.i.d.)
Number of subjects: 29
Study 707970 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (25-50 mg t.i.d.)
Number of subjects: 29
Study 707970 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorimipramine (25-50 mg t.i.d.)
Number of subjects: 29
Study 707970 — intervention group
Group type: COMPARATOR
Intervention: Pre-drug scores (29 patients)
Number of subjects: 29
Study 707970 — intervention group
Group type: COMPARATOR
Intervention: Matched reference group (20 healthy volunteers)
Number of subjects: 29
Study 31227286 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU hCG at the time of GnRHa trigger and placebo at the time of vaginal oocyte retrieval (VOR)
Number of subjects: 30
Study 31227286 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo at the time of GnRHa trigger and 1,500 IU hCG at the time of VOR
Number of subjects: 30
Study 31227286 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hCG given at VOR
Number of subjects: 30
Study 31227286 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant hCG given at the time of trigger
Number of subjects: 30
Study 29238824 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg preoperatively and 600 mg 3 times a day postoperatively)
Number of subjects: 410
Study 29238824 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (lorazepam, 0.5 mg preoperatively followed by inactive placebo postoperatively)
Number of subjects: 410
Study 27472216 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL implantation
Number of subjects: 114
Study 27472216 — intervention group
Group type: COMPARATOR
Intervention: Contact lens correction
Number of subjects: 114
Study 24946631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture, applied to corresponding acupoints based on affected lumbar vertebras, once every day for 30 min, for 3 weeks.
Number of subjects: 40
Study 24946631 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion at Dazhui (GV 14) and Guanyuan (CV 4), warm moxibustion applied once every other day for 1 hour, for 3 weeks.
Number of subjects: 40
Study 24946631 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (acupuncture and moxibustion)
Number of subjects: 40
Study 24946631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 23043386 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN/ribavirin (P/R) for 12 weeks
Number of subjects: 329
Study 23043386 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN for 72 weeks
Number of subjects: 329
Study 23043386 — intervention group
Group type: COMPARATOR
Intervention: Observational control for 72 weeks
Number of subjects: 329
Study 23043386 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN/ribavirin (P/R) for a total of 72 weeks with 24 weeks follow‐up off‐therapy
Number of subjects: 329
Study 20377844 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 596
Study 20377844 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 596
Study 18055932 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 547
Study 18055932 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study 18055932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 547
Study 16784879 — intervention group
Group type: EXPERIMENTAL
Intervention: valdecoxib 10 mg qd
Number of subjects: 530
Study 16784879 — intervention group
Group type: EXPERIMENTAL
Intervention: rofecoxib 25 mg qd
Number of subjects: 530
Study 16784879 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 530
Study 12074059 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused minimally invasive parathyroidectomy (MIP)
Number of subjects: 100
Study 12074059 — intervention group
Group type: COMPARATOR
Intervention: Open parathyroidectomy
Number of subjects: 100
Study 10512278 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus lysine acetyl salicylate (LAS)
Number of subjects: 50
Study 10512278 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50
Study 8766480 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 0
Study 2030245 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-training treatment (average of 44.8 hours of professional contact, including 23.3 hours of phone contacts)
Number of subjects: 55
Study 2030245 — intervention group
Group type: COMPARATOR
Intervention: Service traditionally provided by the juvenile court and community (estimated more than 50 hours of treatment)
Number of subjects: 55
Study 2030245 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-training treatment
Number of subjects: 55
Study 7139000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-relevant content (snake-slide), 25 trials
Number of subjects: 40
Study 7139000 — intervention group
Group type: COMPARATOR
Intervention: Neutral content (rectangular black geometric shape), 25 trials
Number of subjects: 40
Study 31045775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 54
Study 31045775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg
Number of subjects: 54
Study 31045775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31045775 — intervention group
Group type: COMPARATOR
Intervention: Overall opioid consumption
Number of subjects: 54
Study 31045775 — intervention group
Group type: COMPARATOR
Intervention: BSHS (Burn Specific Health Scale)
Number of subjects: 54
Study 28835404 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg every 4 weeks for up to 5 years
Number of subjects: 383
Study 25815710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily walking (30-60 minutes to achieve 10,000 steps/day for 4 weeks)
Number of subjects: 65
Study 23727518 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section (ECS)
Number of subjects: 54
Study 23727518 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal cesarean section (TCS)
Number of subjects: 54
Study 21852252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections
Number of subjects: 306
Study 21852252 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 306
Study 19122539 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with antidepressants
Number of subjects: 0
Study 19122539 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic studies in anxiety disorders
Number of subjects: 0
Study 19122539 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term pharmacological treatment
Number of subjects: 0
Study 17910229 — intervention group
Group type: COMPARATOR
Intervention: Group 1: resin composite restoration without horizontal self‐threading pins or flowable composite (control group)
Number of subjects: 64
Study 17910229 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: resin composite restoration without horizontal self‐threading pins but with a 2 mm thickness of the flowable composite
Number of subjects: 64
Study 17910229 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: resin composite restoration with two horizontal self‐threading pins in the buccal cusp but without flowable composite
Number of subjects: 64
Study 17910229 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: resin composite restoration with two horizontal self‐threading pins in the buccal cusp and flowable composite with a thickness of 2 mm
Number of subjects: 64
Study 15472792 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG) preparation (1-5 x 10^10 cfu/dose)
Number of subjects: 17
Study 15472792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15472792 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG) preparation
Number of subjects: 17
Study 10385840 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant therapy
Number of subjects: 130
Study 10385840 — intervention group
Group type: COMPARATOR
Intervention: Normal control population (N = 31)
Number of subjects: 130
Study 8686677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel function regulator or Harvold activator (treatment)
Number of subjects: 42
Study 8686677 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 42
Study 1887411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidumbacterine
Number of subjects: 43
Study 1887411 — intervention group
Group type: COMPARATOR
Intervention: Salazopyridazine
Number of subjects: 43
Study 6862292 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic grade and size of residual tumor after surgery
Number of subjects: 494
Study 6862292 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic type
Number of subjects: 494
Study 6862292 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of tumor progression
Number of subjects: 494
Study 6862292 — intervention group
Group type: EXPERIMENTAL
Intervention: State of tumor capsules in Stage I
Number of subjects: 494
Study 6862292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascites
Number of subjects: 494
Study 6862292 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 494
Study 6862292 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued chemotherapy
Number of subjects: 494
Study 31916717 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid group (5mL/kg synthetic amniotic fluid)
Number of subjects: 150
Study 31916717 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO group (RhuEPO dissolved in synthetic amniotic fluid)
Number of subjects: 150
Study 31916717 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine feeding protocol without any administration)
Number of subjects: 150
Study 31916717 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 29406482 — intervention group
Group type: EXPERIMENTAL
Intervention: CaHA with triamcinolone acetate
Number of subjects: 20
Study 29406482 — intervention group
Group type: COMPARATOR
Intervention: CaHA with sham saline
Number of subjects: 20
Study 24679362 — intervention group
Group type: EXPERIMENTAL
Intervention: WB‐MWM
Number of subjects: 52
Study 24679362 — intervention group
Group type: EXPERIMENTAL
Intervention: HVLA
Number of subjects: 52
Study 24679362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21938518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antral isolation (PVAI)
Number of subjects: 42
Study 21938518 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein antral isolation plus additional limited ablation (PVAI + CS)
Number of subjects: 42
Study 20156949 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day
Number of subjects: 884
Study 20156949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 884
Study 18245215 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with patient-actors
Number of subjects: 140
Study 18245215 — intervention group
Group type: COMPARATOR
Intervention: Training with manikins
Number of subjects: 140
Study 18245215 — intervention group
Group type: COMPARATOR
Intervention: Teamwork training
Number of subjects: 140
Study 15846460 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 3.5 mg intravenous dose in children
Number of subjects: 0
Study 15846460 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 7 mg intravenous dose in adults
Number of subjects: 0
Study 15846460 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5.25 mg intravenous dose in children (suggested from trial simulations)
Number of subjects: 0
Study 15846460 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (general)
Number of subjects: 0
Study 15846460 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (with TBW as covariate)
Number of subjects: 0
Study 11916954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Insulin Response (AIR)
Number of subjects: 903
Study 11916954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact Proinsulin (PI)
Number of subjects: 903
Study 11916954 — intervention group
Group type: EXPERIMENTAL
Intervention: Split Proinsulin (PI)
Number of subjects: 903
Study 10328634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin-mineral tablets
Number of subjects: 1753
Study 10328634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1753
Study 8734341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily for 3 days)
Number of subjects: 29
Study 8734341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 29
Study 8734341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8734341 — intervention group
Group type: EXPERIMENTAL
Intervention: Soup meal
Number of subjects: 29
Study 8734341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 29
Study 1761452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg once a day
Number of subjects: 58
Study 1761452 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg every 8 h
Number of subjects: 58
Study 6360773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloxilic acid (240 mg/day for 1 month)
Number of subjects: 24
Study 6360773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31215111 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg
Number of subjects: 60
Study 29169294 — intervention group
Group type: EXPERIMENTAL
Intervention: Weiss Functional Impairment Rating Scale (WFIRS) ratings from patients with ADHD
Number of subjects: 62
Study 29169294 — intervention group
Group type: COMPARATOR
Intervention: Simulation condition (individuals instructed to feign ADHD)
Number of subjects: 62
Study 29169294 — intervention group
Group type: COMPARATOR
Intervention: Genuine ADHD patients
Number of subjects: 62